Danaher Stock After Hours (Dec. 11, 2025): DHR Holds a Breakout Level—What to Watch Before the Market Opens Friday

Danaher Corporation is back in the spotlight on December 4, 2025, as fresh bullish research, new institutional buying, and a high‑profile Morgan Stanley upgrade collide with a series of governance investigations into the company’s board. At the same time, Danaher’s own guidance points to a 2026 recovery built on mid‑single‑digit revenue growth and expanding margins.

Danaher Corporation enters December 2025 trading around the mid‑$220s per share, a high‑quality life‑sciences and diagnostics name that continues to command a premium valuation — and attract both bullish analysts and governance‑focused law firms.TS2+1

Danaher’s shares have been on a steady climb in recent weeks, hovering around the $208 mark as of October 21, 2025. This puts the stock roughly back to early-year levels and marks a solid rebound from its summer lows. In fact, DHR has gained about 8% over the past month and 10% over the past quarter, outpacing many peers in the life sciences sectorts2.tech. This rally suggests renewed investor interest in Danaher and its industry, possibly driven by anticipation of the Q3 earnings and optimism around new product developments.